Emergent BioSolutions (EBS) Gross Profit Growth (3y) (2014 - 2026)
Emergent BioSolutions (EBS) Gross Profit Growth (3y) (2014 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Profit Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 6.23% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 3.42% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -0.01% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 8.70% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -3.26% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 28.48% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 8.60% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Emergent BioSolutions | 261.35 Mn | 120.45 Mn | 137.20 Mn | -2.34% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.34% |
| Mar 31, 2026 | 94.67% |
| Dec 31, 2025 | -26.84% |
| Sep 30, 2025 | 16.13% |
| Jun 30, 2025 | -23.11% |
| Mar 31, 2025 | -15.87% |
| Dec 31, 2024 | -52.84% |
| Sep 30, 2024 | -11.80% |
| Mar 31, 2024 | -21.69% |
| Dec 31, 2023 | -7.09% |
| Sep 30, 2023 | -35.94% |
| Jun 30, 2023 | -17.77% |
| Mar 31, 2023 | -53.80% |
| Dec 31, 2022 | -17.38% |
| Sep 30, 2022 | -23.09% |
| Jun 30, 2022 | 4.56% |
| Mar 31, 2022 | 31.47% |
| Dec 31, 2021 | 66.92% |
| Sep 30, 2021 | 33.70% |
| Jun 30, 2021 | 29.95% |